Category Archives: Latest News from DMC Medical

New SureSafe™ Syringe

DMC medical in preparation for the launch of the New SureSafe ™ fully automatic retractable syringe has increased its sales & marketing team in the U.S to four.  Our main focus will be on medical device companies, specialty distributors, GPOs & direct hospital sales.  Own label option will also be available.

Seal of Excellence

DMC medical was awarded a “Seal of Excellence” by the European Commission under its Horizon 20/20 SME Instrument Phase 1 and the EU Framework Programme for Research & Innovation 2014-2020.  The seal of excellence was awarded for our work on the silicone free stopper, advanced copolymer materials and retractable technology.

Exhibitions

DMC medical has increased its presence and customer awareness though its participation in exhibitions in the United States.  Between 2018 and 2020 DMC medical will have exhibited at FIME in Orlando and Miami & the MD&M in Anaheim, California.

Nugen™ Marketing

DMC will undertake a major marketing campaign beginning in August 2017 for the Nugen™ syringe range. The prefilled drug market is seeking alternatives to glass syringes/vials with suitable polymers that are BPA free, chemical & lipid resistant with added toughness and glass-like clarity. The Nugen™ syringe is a suitable and cost-effective alternative. DMC will target the major pharma companies in both Europe and the United States currently prefilling drugs and seeking a superior polymer syringe.

Nugen™

Enquiries increase for the BPA Free Nugen™ syringe with evaluation samples going to the United Kingdom, Turkey, Spain, Russia and the United States. Validations can take a number of months depending on what use the syringe is put to and the drug involved.

BPA (Bisphenol A)

As a result of its classification as “reprotox 1B”, which entered into force in August 2016, BPA formally meets the criteria for identification as a Substance of Very High Concern. In December 2016, ECHA’s Member State Committee (MSC) agreed to identify BPA as SVHC, based on its harmonised classification.

The California Office of Environmental Health Hazard Assessment (OEHHA) lists BPA under Proposition 65 Warnings.